Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LCK | P06239 | 10/20 | 0.61 |
| ▸ | MAPT | P10636 | 3/20 | 0.58 |
| ▸ | TP53 | P04637 | 1/20 | 0.58 |
| ▸ | POLB | P06746 | 2/20 | 0.54 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6057937 | 0.94 | POLB (0.58) | LCKMAPTTP53POLBMTNR1A | |
| SCHEMBL6058227 | 0.89 | LCK (0.62) | LCKPOLB | |
| SCHEMBL6058294 | 0.84 | LCK (0.70) | LCKKMT2AMEN1 | |
| SCHEMBL6057856 | 0.79 | LCK (0.80) | LCKKMT2AMEN1 | |
| SCHEMBL6058241 | 0.79 | LCK (0.68) | LCK | |
| SCHEMBL7623359 | 0.78 | LCK (0.76) | LCK | |
| SCHEMBL7622176 | 0.78 | LCK (0.83) | LCK | |
| SCHEMBL7623364 | 0.78 | LCK (0.81) | LCK | |
| SCHEMBL6058132 | 0.78 | LCK (0.69) | LCKKMT2AMEN1SMN1; SMN2 | |
| SCHEMBL6057903 | 0.77 | LCK (0.79) | LCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1037632-B1 | BENZOTHIAZOLE PROTEIN TYROSINE KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2006-01-11 | — | — | EP | claimed |
| US-6825355-B2 | FOR THERAPY OF IMMUNOLOGIC DISORDERS SUCH AS TRANSPLANT REJECTION, RHEUMATOID ARTHRITIS. MULTIPLE SCLEROSIS, INFLAMMATORY BOWEL DISEASE, LUPUS, GRAFT VS. HOST DISEASE | BRISTOL-MYERS SQUIBB CO. | 2004-11-30 | — | — | US | claimed |
| US-20020123484-A1 | Benzothiazole protein trosine kinase inhibitors | DAS JAGABNDHU (US) | 2002-09-05 | — | — | US | claimed |
| US-6825355-B2 | FOR THERAPY OF IMMUNOLOGIC DISORDERS SUCH AS TRANSPLANT REJECTION, RHEUMATOID ARTHRITIS. MULTIPLE SCLEROSIS, INFLAMMATORY BOWEL DISEASE, LUPUS, GRAFT VS. HOST DISEASE | BRISTOL-MYERS SQUIBB CO. | 2004-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020123484-A1 | Benzothiazole protein trosine kinase inhibitors | TXK, LTK, JAK2 | LCK 20/4885MAPT 780/4885TP53 487/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.